» Articles » PMID: 31573977

Increased Lipogenesis and Impaired β-oxidation Predict Type 2 Diabetic Kidney Disease Progression in American Indians

Abstract

BACKGROUNDIn this study, we identified the lipidomic predictors of early type 2 diabetic kidney disease (DKD) progression, which are currently undefined.METHODSThis longitudinal study included 92 American Indians with type 2 diabetes. Serum lipids (406 from 18 classes) were quantified using mass spectrometry from baseline samples when iothalamate-based glomerular filtration rate (GFR) was at least 90 mL/min. Affymetrix GeneChip Array was used to measure renal transcript expression. DKD progression was defined as at least 40% decline in GFR during follow-up.RESULTSParticipants had a mean age of 45 ± 9 years and median urine albumin/creatinine ratio of 43 (interquartile range 11-144). The 32 progressors had significantly higher relative abundance of polyunsaturated triacylglycerols (TAGs) and a lower abundance of C16-C20 acylcarnitines (ACs) (P < 0.001). In a Cox regression model, the main effect terms of unsaturated free fatty acids and phosphatidylethanolamines and the interaction terms of C16-C20 ACs and short-low-double-bond TAGs by categories of albuminuria independently predicted DKD progression. Renal expression of acetyl-CoA carboxylase-encoding gene (ACACA) correlated with serum diacylglycerols in the glomerular compartment (r = 0.36, and P = 0.006) and with low-double-bond TAGs in the tubulointerstitial compartment (r = 0.52, and P < 0.001).CONCLUSIONCollectively, the findings reveal a previously unrecognized link between lipid markers of impaired mitochondrial β-oxidation and enhanced lipogenesis and DKD progression in individuals with preserved GFR. Renal acetyl-CoA carboxylase activation accompanies these lipidomic changes and suggests that it may be the underlying mechanism linking lipid abnormalities to DKD progression.TRIAL REGISTRATIONClinicalTrials.gov, NCT00340678.FUNDINGNIH R24DK082841, K08DK106523, R03DK121941, P30DK089503, P30DK081943, and P30DK020572.

Citing Articles

Metabolomic and Lipidomic Profiling for Pre-Transplant Assessment of Delayed Graft Function Risk Using Chemical Biopsy with Microextraction Probes.

Warmuzinska N, Luczykowski K, Stryjak I, Wojtal E, Woderska-Jasinska A, Masztalerz M Int J Mol Sci. 2025; 25(24.

PMID: 39769265 PMC: 11728147. DOI: 10.3390/ijms252413502.


Unraveling Diabetic Kidney Disease: The Roles of Mitochondrial Dysfunction and Immunometabolism.

Narongkiatikhun P, Choi Y, Hampson H, Gotzamanis J, Zhang G, van Raalte D Kidney Int Rep. 2024; 9(12):3386-3402.

PMID: 39698345 PMC: 11652104. DOI: 10.1016/j.ekir.2024.09.019.


Crosstalk between glomeruli and tubules.

Fogo A, Harris R Nat Rev Nephrol. 2024; 21(3):189-199.

PMID: 39643696 DOI: 10.1038/s41581-024-00907-0.


Metabolomics profiling in multi-ancestral individuals with type 2 diabetes in Singapore identified metabolites associated with renal function decline.

Chen Y, Torta F, Koh H, Benke P, Gurung R, Liu J Diabetologia. 2024; 68(3):557-575.

PMID: 39621102 DOI: 10.1007/s00125-024-06324-z.


Metabolic Chaos in Kidney Disease: Unraveling Energy Dysregulation.

Gupta P, Zhu S, Gui Y, Zhou D J Clin Med. 2024; 13(22).

PMID: 39597916 PMC: 11594442. DOI: 10.3390/jcm13226772.


References
1.
Schmid H, Boucherot A, Yasuda Y, Henger A, Brunner B, Eichinger F . Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes. 2006; 55(11):2993-3003. DOI: 10.2337/db06-0477. View

2.
Niewczas M, Sirich T, Mathew A, Skupien J, Mohney R, Warram J . Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int. 2014; 85(5):1214-24. PMC: 4072128. DOI: 10.1038/ki.2013.497. View

3.
Calzada E, Onguka O, Claypool S . Phosphatidylethanolamine Metabolism in Health and Disease. Int Rev Cell Mol Biol. 2016; 321:29-88. PMC: 4778737. DOI: 10.1016/bs.ircmb.2015.10.001. View

4.
Saulnier P, Gand E, Velho G, Mohammedi K, Zaoui P, Fraty M . Association of Circulating Biomarkers (Adrenomedullin, TNFR1, and NT-proBNP) With Renal Function Decline in Patients With Type 2 Diabetes: A French Prospective Cohort. Diabetes Care. 2016; 40(3):367-374. DOI: 10.2337/dc16-1571. View

5.
Reis A, Rudnitskaya A, Chariyavilaskul P, Dhaun N, Melville V, Goddard J . Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease. J Lipid Res. 2014; 56(2):413-22. PMC: 4306694. DOI: 10.1194/jlr.M055624. View